Restricted accessResearch articleFirst published online 2018-06
Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder
The purpose of this open-label study was to examine the effects of long-acting methylphenidate (MPH) treatment on irritability and related emotional symptoms associated with disruptive mood dysregulation disorder (DMDD) in youth with comorbid attention-deficit/hyperactivity disorder (ADHD).
Methods:
The sample included 22 medication-free male and female subjects (ages 9–15) who met criteria for both DMDD and ADHD. Participants underwent a 4-week trial of long-acting MPH treatment (Concerta®), with weekly dosing increases until a therapeutic dose was reached. Repeated measures t-tests were used to compare pre- and posttreatment ratings of primary and secondary measures. The primary outcome was self-report irritability. Secondary outcomes included parent and child ratings of emotional frequency, emotional lability, and negative affect (NA). Multiple regression was used to examine the impact baseline hyperactivity, age, gender, race, socioeconomic status, or comorbid diagnosis had on treatment outcomes.
Results:
Significant improvements (medium to large effect sizes) in child-rated irritability as well as parent and child ratings of emotional lability, NA, and anger were found. As anticipated, ADHD symptoms also improved. While a majority of the sample saw improvement in child-rated irritability (71%), symptoms worsened a small proportion (19%), and an even smaller portion experienced no change (10%). No demographics, psychiatric comorbidities, or severity of ADHD symptoms influenced treatment outcomes.
Conclusions:
Study findings suggest that MPH treatment significantly improved mood and emotional symptoms associated with DMDD comorbid with ADHD. These findings, coupled with good tolerability in this open-label pilot study supports further research into the use of MPH as a first-line treatment for DMDD. Future work examining MPH treatment of youth with DMDD with and without comorbid ADHD is needed.
Get full access to this article
View all access options for this article.
References
1.
AhmannPA, WaltonenSJ, TheyeFW, OlsonKA, Van EremAJ: Placebo-controlled evaluation of Ritalin side effects. Pediatrics, 91:1101–1106, 1993.
2.
AmanMG, BuksteinOG, GadowKD, ArnoldLE, MolinaBS, McNamaraNK, Rundberg-RiveraEV, LiX, KippH, SchneiderJ, ButterEM, BakerJ, SprafkinJ, RiceRRJr, BangaloreSS, FarmerCA, AustinAB, Buchan-PageKA, BrownNV, HurtEA, GrondhuisSN, FindlingRL: What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry, 53:47–60.e41, 2014.
3.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000.
4.
AndradeSE, LoJC, RoblinD, FouayziH, ConnorDF, PenfoldRB, ChandraM, ReedG, GurwitzJH: Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics, 128:1135–1141, 2011.
BawejaR, BelinPJ, HumphreyHH, BabocsaiL, PariseauME, WaschbuschDA, HoffmanMT, AkinnusiOO, HaakJL, PelhamWE, WaxmonskyJG: The effectiveness and tolerability of central nervous system stimulants in school-age children with attention-deficit/hyperactivity disorder and disruptive mood dysregulation disorder across home and school. J Child Adolesc Psychopharmacol, 26:154–163, 2016.
7.
BerkowitzL. Aggression: Its Causes, Consequences, and Control. New York, NY: Mcgraw-Hill Book Company, 1993.
8.
BiedermanJ, FaraoneS, WozniakJ, MickE, KwonA, AleardiM: Further evidence of unique developmental phenotypic correlates of pediatric bipolar disorder: Findings from a large sample of clinically referred preadolescent children assessed over the last 7 years. J Affect Disord, 82, S45–S58, 2004.
9.
BiedermanJ, KrishnanS, ZhangY, McGoughJJ, FindlingRL: Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther, 29:450–463, 2007.
10.
BirnbaumML, SaitoE, GerhardT, WintersteinA, OlfsonM, KaneJM, CorrellCU: Pharmacoepidemiology of antipsychotic use in youth with ADHD: Trends and clinical implications. Curr Psychiatry Rep, 15:382, 2013.
11.
BladerJC, PliszkaSR, KafantarisV, SauderC, PosnerJ, FoleyCA, CarlsonGA, CrowellJA, MarguliesDM: Prevalence and treatment outcomes of persistent negative mood among children with attention-deficit/hyperactivity disorder and aggressive behavior. J Child Adolesc Psychopharmacol, 26:164–173, 2016.
12.
BussAH, DurkeeA: An inventory for assessing different kinds of hostility. J Consult Psychol, 21:343, 1957.
13.
CapraraGV: The measure of aggression: Research contribution for the construction and validation of two scales for the measurement of irritability and emotional susceptibility. [In Italian]. Italian Journal of Psychology, 10:91–111, 1983.
14.
CapraraGV, CinanniV, D'ImperioG, PasseriniS, RenziP, TravagliaG: Indicators of impulsive aggression: Present status of research on irritability and emotional susceptibility scales. Pers Individ Dif, 6:665–674, 1985.
15.
CapraraGV, PacielloM, GerbinoM, CuginiC: Individual differences conducive to aggression and violence: Trajectories and correlates of irritability and hostile rumination through adolescence. Aggress Behav, 33:359–374, 2007.
16.
ChelaruMI, YangPB, DafnyN: Sex differences in the behavioral response to methylphenidate in three adolescent rat strains (WKY, SHR, SD). Behav Brain Res, 226:8–17, 2012.
17.
Churn-ShiouhG, Ching-JuiC, Fang-JuT, Pei-FongC, Susan Shur-FenG: Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: A nested, matched case-control study. Bipolar Disord, 12:253–263, 2010.
18.
CohenJ: Statistical Power Analysis for the Behavioral Sciences. New York, NY, Routledge Academic, 1987.
19.
CopelandWE, AngoldA, CostelloEJ, EggerH: Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder. Am J Psychiatry, 170:173–179, 2013.
20.
IBM Corp: IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp, 2013.
21.
de la CruzLF, SimonoffE, McGoughJJ, HalperinJM, ArnoldLE, StringarisA: Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: Results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry, 54:62–70.e3, 2015.
22.
DicksteinDP, LeibenluftE: Beyond dogma: From diagnostic controversies to data about pediatric bipolar disorder and children with chronic irritability and mood dysregulation. Isr J Psychiatry Relat Sci, 49:52, 2012.
23.
DicksteinDP, TowbinKE, Van Der VeenJW, RichBA, BrotmanMA, KnopfL, OnelioL, PineDS, LeibenluftE: Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. J Child Adolesc Psychopharmacol, 19:61–73, 2009.
EkkekakisP: The Measurement of Affect, Mood, and Emotion: A Guide for Health-Behavioral Research. Cambridge: Cambridge University Press, 2013.
26.
FeiseRJ: Do multiple outcome measures require p-value adjustment?. BMC Med Res Methodol, 2, 8, 2002.
27.
FirestoneP, MustenLM, PistermanS, MercerJ, BennettS: Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: A double-blind placebo-controlled study. J Child Adolesc Psychopharmacol, 8:13–25, 1998.
28.
FitzpatrickPA, KlormanR, BrumaghimJT, BorgstedtAD: Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder. J Am Acad Child Adolesc Psychiatry, 31:226–234, 1992.
29.
GadowKD, BrownNV, ArnoldLE, Buchan-PageKA, BuksteinOG, ButterE, FarmerCA, FindlingRL, KolkoDJ, MolinaBS, RiceRRJr, SchneiderJ, AmanMG: Severely aggressive children receiving stimulant medication versus stimulant and risperidone: 12-month follow-up of the TOSCA trial. J Am Acad Child Adolesc Psychiatry, 55:469–478, 2016.
30.
GreenbergLM, DeemMA, McMahonS: Effects of dextroamphetamine, chlorpromazine, and hydroxyzine on behavior and performance in hyperactive children. Am J Psychiatry, 129:532–539, 1972.
HiltRJ, ChaudhariM, BellJF, WolfC, KoprowiczK, KingBH: Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents. J Child Adolesc Psychopharmacol, 24:83–89, 2014.
33.
HughesAA, KendallPC: Psychometric properties of the positive and negative affect scale for children (PANAS-C) in children with anxiety disorders. Child Psychiatry Hum Dev, 40:343–352, 2009.
34.
IzardCE, LiberoDZ, PutnamP, HaynesOM: Stability of emotion experiences and their relations to traits of personality. J Pers Soc Psychol, 64:847–860, 1993.
35.
KaufmanJ, BirmaherB, BrentD, RaoU, FlynnC, MoreciP, WilliamsonD, RyanN: Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry, 36:980–988, 1997.
36.
KriegerFV, PheulaGF, CoelhoR, ZeniT, TramontinaS, ZeniCP, RohdeLA: An open-label trial of risperidone in children and adolescents with severe mood dysregulation. J Child Adolesc Psychopharmacol, 21:237–243, 2011.
37.
LaurentJ, CatanzaroSJ, JoinerTEJr, RudolphKD, PotterKI, LambertS, OsborneL, GathrightT: A measure of positive and negative affect for children: Scale development and preliminary validation. Psychol Assess, 11:326, 1999.
38.
LeeJ, GrizenkoN, BhatV, SenguptaS, PolotskaiaA, JooberR: Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatry, 11:70, 2011.
39.
LeibenluftE: Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. Am J Psychiatry, 168:129–142, 2011.
40.
LeibenluftE, CharneyDS, TowbinKE, BhangooRK, PineDS: Defining clinical phenotypes of juvenile mania. Am J Psychiatry, 160:430–437, 2003.
41.
LeibenluftE, StoddardJ: The developmental psychopathology of irritability. Dev Psychopathol, 25(4 Pt 2):1473–1487, 2013.
42.
MaayanL, CorrellCU: Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol, 21:517–535, 2011.
43.
MitchellRH, TimminsV, CollinsJ, ScavoneA, IskricA, and GoldsteinBI. Prevalence and correlates of disruptive mood dysregulation disorder among adolescents with bipolar disorder. J Child Adolesc Psychopharmacol, 26:147–153, 2016.
44.
MordenNE, GoodmanD: Pediatric polypharmacy: Time to lock the medicine cabinet?. Arch Pediatr Adolesc Med, 166:91–92, 2012.
45.
PapolosD, MattisS, GolshanS, MolayF: Fear of harm, a possible phenotype of pediatric bipolar disorder: A dimensional approach to diagnosis for genotyping psychiatric syndromes. J Affect Disord, 118:28–38, 2009.
46.
PappadopulosE, WoolstonS, ChaitA, PerkinsM, ConnorDF, JensenPS: Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size. J Can Acad Child Adolesc Psychiatry, 15:27–39, 2006.
47.
ParmarA, VatsD, ParmarR, AligetiM: Role of naltrexone in management of behavioral outbursts in an adolescent male diagnosed with disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol, 24:594–595, 2014.
48.
PliszkaSR, BrowneRG, OlveraRL, WynneSK: A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 39:619–626, 2000.
49.
RieppiR, GreenhillLL, FordRE, ChuangS, WuM, DaviesM, AbikoffHB, ArnoldLE, ConnersCK, ElliottGR, HechtmanL, HinshawSP, HozaB, JensenPS, KraemerHC, MarchJS, NewcornJH, PelhamWE, SevereJB, SwansonJM, VitielloB, WellsKC, WigalT: Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry, 41:269–277, 2002.
50.
RothmanKJ: No adjustments are needed for multiple comparisons. Epidemiology, 1:43–46, 1990.
51.
SeidaJC, SchoutenJR, BoylanK, NewtonAS, MousaviSS, BeaithA, VandermeerB, DrydenDM, CarreyN: Antipsychotics for children and young adults: A comparative effectiveness review. Pediatrics, 129:e771–e784, 2012.
52.
ShawP, StringarisA, NiggJ, LeibenluftE: Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry, 171:276–293, 2014.
53.
ShieldsA, CicchettiD: Emotion regulation among school-age children: The development and validation of a new criterion Q-sort scale. Dev Psycholgy, 33:906, 1997.
54.
SinzigJ, DöpfnerM, LehmkuhlG, German Methylphenidate StudyGroup, UebelH, SchmeckK, PoustkaF, GerberWD, GünterM, KnölkerU, GehrkeM, HässlerF, ReschF, BrüngerM, OseC, FischerR.. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 4:421–432, 2007.
55.
Steene-JohannessenJ, AnderssenSA, Van der PloegHP, HendriksenIJ, DonnellyAE, BrageS, EkelundU: Are self–report measures able to define individuals as physically active or inactive?. Med Sci Sports Exerc, 48: 235–244, 2016.
56.
StringarisA, MaughanB, CopelandWS, CostelloEJ, AngoldA: Irritable mood as a symptom of depression in youth: Prevalence, developmental, and clinical correlates in the Great Smoky Mountains Study. J Am Acad Child Adolesc Psychiatry, 52:831–840, 2013.
57.
StuckelmanZD, MulqueenJM, Ferracioli-OdaE, CohenSC, CoughlinCG, LeckmanJF, BlochMH: Risk of irritability with psychostimulant treatment in children with ADHD: A meta-analysis. J Clin Psychiatry, 78:e648–e655, 2017.
58.
SwansonJM, WigalSB, WigalT, Sonuga-BarkeE, GreenhillLL, BiedermanJ, KollinsS, NguyenAS, DeCoryHH, Hirshe DirksenSJ, Hatch SJ; COMACS StudyGroup: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics, 113:e206–e216, 2004.
59.
TourianL, LeBoeufA, BretonJJ, CohenD, GignacM, LabelleR, GuileJM, RenaudJ: Treatment options for the cardinal symptoms of disruptive mood dysregulation disorder. J Can Acad Child Adolesc Psychiatry, 24:41–54, 2015.
60.
WaxmonskyJ, PelhamWE, GnagyE, CummingsMR, O'ConnorB, MajumdarA, VerleyJ, HoffmanMT, MassettiGA, Burrows-MacLeanL, FabianoGA, WaschbuschDA, ChackoA, ArnoldFW, WalkerKS, GarefinoAC, RobbJA. The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. J Child Adolesc Psychopharmacol, 18:573–588, 2008.
61.
WaxmonskyJ, WaschbuschDA, BelinP, LiT, BabocsaiL, HumpheryH, PariseauME, BabinskiDE, HoffmanMT, HaakJL, MazzantJR, FabianoGA, PettitJW, FallahazadN, PelhamWE: A randomized clinical trial of an integrative group therapy for children with severe mood dysregulation. J Am Acad Child Adolesc Psychiatry, 55:196–207, 2016.
62.
WigginsJL, BrotmanMA, AdlemanNE, KimP, OakesAH, ReynoldsRC, ChenG, PineDS, LeibenluftE: Neural correlates of irritability in disruptive mood dysregulation and bipolar disorders. Am J Psychiatry, 173:722–730, 2016.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
